Alpha-fetoprotein

Structure

AFP is a glycoprotein of 591 amino acids and a carbohydrate moiety.

Function

The function of AFP in adult humans is unknown. AFP is the most abundant plasma protein found in the human fetus. In the fetus, AFP is produced by both the liver and the yolk sac. It is believed to function as a carrier protein (similar to albumin) that transports materials such as fatty acids to cells. Maternal plasma levels rise until the 32nd week of pregnancy, when they begin to decline. They decrease rapidly after birth. Normal adult levels in the newborn are usually reached by the age of 8 to 12 months. While the function in humans is unknown, in rodents it binds estradiol to prevent the transport of this hormone across the placenta to the fetus. The main function of this is to prevent the virilization of female fetuses. As human AFP does not bind estrogen, its function in humans is less clear. In human liver cancer, AFP is found to bind glypican-3 (GPC3), another oncofetal antigen.

The rodent AFP system can be overridden with massive injections of estrogen, which overwhelm the AFP system and will masculinize the fetus. The masculinizing effect of estrogens may seem counter-intuitive since estrogens are critical for the proper development of female secondary characteristics during puberty. However, this is not the case prenatally. Gonadal hormones from the testes, such as testosterone and anti-Müllerian hormone, are required to cause development of a phenotypic male. Without these hormones, the fetus will develop into a phenotypic female even if genetically XY. The conversion of testosterone into estradiol by aromatase in many tissues may be an important step in masculinization of that tissue. Masculinization of the brain is thought to occur both by conversion of testosterone into estradiol by aromatase, but also by de novo synthesis of estrogens within the brain. Thus, AFP may protect the fetus from maternal estradiol that would otherwise have a masculinizing effect on the fetus, but its exact role is still controversial.

Serum levels

Main article: Elevated alpha-fetoprotein

Maternal

Fetal AFP levels can be monitored in the urine of pregnant women. Since AFP is quickly cleared from the mother's serum via her kidneys, maternal urine AFP correlates with fetal serum levels, although the maternal urine level is much lower than the fetal serum level. AFP levels rise until about week 32. Maternal serum alpha-fetoprotein (MSAFP) screening is performed at 16 to 18 weeks of gestation. If MSAFP levels indicate an anomaly, amniocentesis may be offered to the patient.

Infants

The normal range of AFP for adults and children is variously reported as under 50, under 10, or under 5 ng/mL. At birth, normal infants have AFP levels four or more orders of magnitude above this normal range, that decreases to a normal range over the first year of life.

During this time, the normal range of AFP levels spans approximately two orders of magnitude. Correct evaluation of abnormal AFP levels in infants must take into account these normal patterns.

Very high AFP levels may be subject to hooking (see Tumor marker), which results in the level being reported significantly lower than the actual concentration. This is important for analysis of a series of AFP tumor marker tests, e.g. in the context of post-treatment early surveillance of cancer survivors, where the rate of decrease of AFP has diagnostic value.

Clinical significance

Main article: Elevated alpha-fetoprotein

Measurement of AFP is generally used in two clinical contexts. First, it is measured in pregnant women through the analysis of maternal blood or amniotic fluid as a screening test for certain developmental abnormalities, such as aneuploidy. Second, serum AFP level is elevated in people with certain tumors, and so it is used as a biomarker to follow these diseases. Some of these diseases are listed below:

• Developmental birth defects associated with elevated AFP
  • Omphalocele
  • Gastroschisis
  • Neural tube defects: elevated α-fetoprotein in amniotic fluid and maternal serum
• Tumors associated with elevated AFP
  • Hepatocellular carcinoma
  • Metastatic disease affecting the liver
  • Nonseminomatous germ cell tumors
  • Yolk sac tumor
• Other conditions associated with elevated AFP
  • Ataxia telangiectasia: elevated AFP is used as one factor in diagnosis

A peptide derived from AFP that is referred to as AFPep is claimed to possess anti-cancer properties.

In the treatment of testicular cancer it is paramount to differentiate seminomatous and nonseminomatous tumors. This is typically done pathologically after removal of the testicle and confirmed by tumor markers. However, if the pathology is pure seminoma but the AFP is elevated, the tumor is treated as a nonseminomatous tumor because it contains yolk sac (nonseminomatous) components.

References

References

1. Lawrence, Eleanor. "AFP".
2. (1977). "Structure and function of alpha-fetoprotein". Annual Review of Medicine.
3. (May 2001). "Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants". Experimental Biology and Medicine.
4. (July 1983). "Linkage of the evolutionarily-related serum albumin and alpha-fetoprotein genes within q11-22 of human chromosome 4". American Journal of Human Genetics.
5. "Entrez Gene: Alpha-fetoprotein".
6. "Entry - *104150 - ALPHA-FETOPROTEIN; AFP - OMIM".
7. (2014). "Maternal Child Nursing Care". Elsevier.
8. (May 1991). "Human alpha-fetoprotein primary structure: a mass spectrometric study". Biochemistry.
9. (1995). "Biochemical characteristics and clinical applications of alpha-fetoprotein isoforms". Anticancer Research.
10. (1997). "Regulation and activities of alpha-fetoprotein". Critical Reviews in Eukaryotic Gene Expression.
11. Mizejewski Gj (2003) Levels of Alpha-Fetoprotein During regnancy and Early Infancy in Normal and Disease States; Obs Gyn Survey 804-82658(12):
12. (2002). "Behavioral Endocrinology". MIT Press.
13. (October 2024). "A proteomic atlas of glypican-3 interacting partners: Identification of alpha-fetoprotein and other extracellular proteins as potential immunotherapy targets in liver cancer". Proteoglycan Research.
14. (December 2000). "Hormones in male sexual development". Genes & Development.
15. (Jan 1992). "Aromatase enzyme activity and sex determination in chickens.". Science.
16. (Jan 2008). "Role for estradiol in female-typical brain and behavioral sexual differentiation.". Frontiers in Neuroendocrinology.
17. (Jun 2004). "Hormonal modulation of singing: hormonal modulation of the songbird brain and singing behavior.". Annals of the New York Academy of Sciences.
18. (2018). "Maternal child nursing care : maternity pediatric". Elsevier.
19. (March 1992). "Alpha-fetoprotein levels in normal adults". The American Journal of the Medical Sciences.
20. (February 1977). "Mean alpha-fetoprotein values of 1,333 males over 15 years by age groups". Digestion.
21. (1998). "Alpha 1-fetoprotein (AFP) reference values in infants up to 2 years of age". Pediatric Hematology and Oncology.
22. (October 1997). "Alpha-fetoprotein (AFP) levels in normal children". European Journal of Pediatric Surgery.
23. (January 1989). "Serum alpha-fetoprotein levels in normal infants: a reappraisal of regression analysis and sex difference". Journal of Pediatric Gastroenterology and Nutrition.
24. (April 1987). "Plasma alpha fetoprotein reference ranges in infancy: effect of prematurity". Archives of Disease in Childhood.
25. (November 2004). "Alpha-fetoprotein in the early neonatal period--a large study and review of the literature". Clinica Chimica Acta; International Journal of Clinical Chemistry.
26. (1985). "Alfa-Fetoprotein and Congenital Disorders". Academic Press.
27. (July 2006). "The hook effect: a need for constant vigilance". Annals of Clinical Biochemistry.
28. (September 1990). "[Alpha fetoprotein concentration in the amniotic fluid in normal pregnancy and in pregnancy complicated by fetal anomaly]". Orvosi Hetilap.
29. (December 2005). "Down syndrome screening in the first and second trimesters: what do the data show?". Seminars in Perinatology.
30. (2012). "First-trimester screening for neural tube defects using alpha-fetoprotein". Fetal Diagnosis and Therapy.
31. Le, Tao. First Aid for the USMLE Step 1 2013. New York: McGraw-Hill Medical, 2013. Print.
32. (2013). "A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma.". Digestion.
33. (October 2005). "Molecular pathology of ataxia telangiectasia". Journal of Clinical Pathology.
34. (April 2000). "Alpha-fetoprotein-derived antiestrotrophic octapeptide". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.
35. (September 1975). "Digitoxin metabolism by rat liver microsomes". Biochemical Pharmacology.